To evaluate sputum smear fluorescein diacetate (FDA) vital staining to predict culture-defined failure and rifampicin (RMP) resistance. D E S I G N : A retrospective, operational study. R E S U LT S : A total of 1633 episodes of auramine smeardefined late conversion and failure could be evaluated (respectively 640 and 584 on first treatment and 185 and 224 on retreatment). Negative FDA was 95% predictive of negative culture in patients on first treatment, while its positive predictive value was around 95% during retreatment. The predictive value of a positive (not scanty) result for RMP resistance or environmental nontuberculous mycobacteria (NTM) was at least 90%, except in late converters on first-line treatment; a negative result was over 95% exclusive of the same except in r etreatment failures. FDA correctly identified 88-98% of all RMP resistance. C O N C L U S I O N S : FDA staining increased the proportion of tuberculosis patients put on second-line treatment without receiving the standard first-line retreatment regimen. In our setting, with excellent microscopy, late case presentation and low resistance prevalence, it proved indispensable for efficient culture and referrals of early suspects for rapid drug susceptibility testing (DST). In other settings with low prevalence of NTM and difficult access to accurate and rapid DST, FDA-positive failures might even be considered for immediate start of secondline treatment. K E Y W O R D S : microscopy; multidrug resistance; viability; culture; drug susceptibility testing IN CONTEXTS with effective anti-tuberculosis treatment and low rates of primary multidrug-resistant tuberculosis (MDR-TB), excellent microscopy for acidfast bacilli (AFB) may lead to frequent over-diagnosis of fi rst treatment failure, due to confusion with late excretion of dead bacilli. 1,2 National control programmes (NTPs) often attempt to screen late AFBsmear converters for MDR-TB, but this is highly ineffi cient. 3 Culture and drug susceptibility testing (DST) will generally fail, while line-probe assay (LPA) DST may yield inconclusive results due to the presence of degraded DNA.
IN CONTEXTS with effective anti-tuberculosis treatment and low rates of primary multidrug-resistant tuberculosis (MDR-TB), excellent microscopy for acidfast bacilli (AFB) may lead to frequent over-diagnosis of fi rst treatment failure, due to confusion with late excretion of dead bacilli. 1,2 National control programmes (NTPs) often attempt to screen late AFBsmear converters for MDR-TB, but this is highly ineffi cient. 3 Culture and drug susceptibility testing (DST) will generally fail, while line-probe assay (LPA) DST may yield inconclusive results due to the presence of degraded DNA.
We previously reported the high predictive value of vital staining with fl uorescein-diacetate (FDA) for the diagnosis of true (culture-proven) treatment failure, showing over 95% correlation with growth in culture. Based on this study conducted in a reference laboratory, we recommended FDA for MDR-TB screening. 4 Since 2008, the FDA technique has been used in conjunction with DST on slides (slide DST) 4 by four regional laboratories for earlier switch to the highly effi cient Bangladesh gatifl oxacin second-line regimen. 5 This operational study aimed to retrospectively evaluate the usefulness of FDA screening by referral indication in terms of its predictive values with mycobacterial culture and DST as references, and its overall contribution to MDR-TB management.
The Damien Foundation (DF) Bangladesh Project implements TB control on behalf of the NTP in a population of about 25 million people who often present with advanced but drug-susceptible disease. 6, 7 Regimens with rifampicin (RMP) throughout are used for new (Category I) and retreatment cases (Category II). Treatment is directly observed, using all possible providers. 8 In accordance with NTP guidelines, treatment failure is declared from 5 months of treatment onwards, even for a single AFB. The same cut-off is used for the defi nition of smear-positive relapse (at least one AFB in one sputum smear at any time after cure or treatment completion).
METHODS

Patients and specimens
Initially, all types of MDR-TB suspects were eligible for FDA smear: Category I and II failures and relapses
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as well as late converters (smear-positive after respectively 3 and 4 months of an extended intensive phase), with any number of AFB on Ziehl-Neelsen (ZN) or auramine smear. Samples were generally examined fresh, referring the patient to a regional FDA and slide DST laboratory, where auramine microscopy was repeated in conjunction with FDA staining. Another specimen was collected in cetylpyridinium chloride preservative for culture on Löwenstein-Jensen (LJ) medium at the project reference laboratory. LJ DST was performed at the Antwerp supranational reference laboratory (SRL) on systematically referred isolates.
FDA procedure
The following modifi cations to our previous technique were introduced:
• staining unfi xed smears for 30 min with FDA working solution, 3 min destaining with 0.5% acid alcohol and 10 min with phenol 5% for sterilisation; 4 • quenching with 0.5% aqueous potassium permanganate for 1 min after destaining; • reading one smear length at 200× magnifi cation on a light-emitting diode (LED) fl uorescence microscope (rather than the 1000× required by mercury vapour systems), using FLUOLED ® Easy module (Fraen Corporation Srl, Settimo Milanese, Italy) with 450 nm LED and fi lters for auramine on Olympus CX21 or CX31 microscopes (Olympus Corporation, Tokyo, Japan); • preventing precipitation and evaporation from less concentrated stocks (500 μl FDA stock aliquots at 0.5% weight/volume in acetone, instead of 100 μl at 5%); • adding a positive control smear from a newly diagnosed smear-positive case.
Reference laboratory tests
Decontamination, primary culture and DST on LJ were performed using standard methods, as previously described. 6 Our slide DST technique was slightly modifi ed from the earlier description: 4
• sputum was homogenised with N-acetylcysteine/ citrate for even smearing; • selective antibiotics replaced acid decontamination; 9 • Middlebrook 7H9 with 10% goat's serum replaced Sula medium; • a para-nitrobenzoic acid 500 μg/ml bottle was added for the identifi cation of NTM. 10 NTM identifi cation relied on p-nitrobenzoic acid growth and microcolony morphology on slide DST, in addition to 16S r-RNA analysis on LJ isolates referred to the SRL.
Ethics considerations
Because of its retrospective nature, the study was not submitted to an ethical committee. Table 1 shows an overview of all 4512 FDA tests performed by the four laboratories during these 3 years by indication. Relapses after Category I are underrepresented, as this indication was soon dropped considering the high number and the low yield of MDR-TB. FDA smears were performed for 1477 Category I and 292 Category II late converters, and 748 and 317 failures. The percentage of negative results varied from almost 80% among late Category I converters to 21% for Category II relapses. Scanty positive results (converted to 1-9 per 100 high-power fi elds) 11 made up 41% of all FDA-positive smears from late converters, and less in the other groups. Table 2 shows the results of FDA staining compared with liquid and/or solid medium culture results (as far as available; contamination excluded) for the 2834 late converters and smear-defi ned failures only. One result was counted per patient/indication, keeping the most positive result in case of discordance. The specifi city and negative predictive value (NPV) of FDA were high among Category I late converters and failures (respectively n = 640, specifi city 91% and NPV 95% and n = 584, specifi city 95% and 97% NPV). Sensitivity and positive predictive value (PPV) were higher for Category II patients (93% and 94% among 185 late converters, 94% and 97% among 224 failures). Sensitivity was only around 80-85% for Category I samples, but the PPV was lowest (69% for late converters and 83% for failures); on Category II, specifi city among failures was 91%, while the NPV remained moderate, at 83%, with slightly better values for late converters (93% specifi city, 91% NPV). Table 3 shows RMP-resistant (Rr) TB and NTM detected by indication and FDA result, and the PPV for both together, for culture-positive specimens Table 4 shows the diagnostic accuracy for viable AFB, Rr and NTM (all samples). Few Rr or NTM were isolated from FDA-negative samples, yielding a 95-97% correct prediction of clinically unimportant AFB positivity, except in the group of Category II failures (85%). NTM represented about half of the missed late converters on both regimens; however, missed failures were usually Rr. Scanty positive FDA smears were poorly predictive of Rr for Category I late converters (16% Rr, no NTMs identifi ed in this category) or failures (29% Rr, 45% when including NTM). Scanty positive FDA smears were more predictive during Category II, particularly considering Rr TB and NTM together (75-87%). A positive FDA smear indicated Rr TB in 67% of late Category I converters (no NTM in this group), increasing to 82-88% in the other groups (or 90-93% adding the NTM). Overall accuracy of the FDA smears in including or excluding Rr TB or NTM was around 90% in all groups except Category I late converters (86%, 95% confi dence interval [CI] 83-89). Of all Rr, 90%/88% were FDApositive or scanty among Category I late converters/ failures respectively and 98%/96% among Category II late converters/failures. Overall, this was 93% (95%CI 90-95). These proportions were slightly lower (91%, 95%CI 88-93%) when NTM was included. Table 5 proportion of these were diagnosed early, based on FDA and slide DST, before Category II treatment was given. A slightly higher proportion could not be confi rmed by conventional DST as Rr in 2008 (13%) and 2009 (10%), but in 2010 this proportion had fallen to the previous level (7%).
RESULTS
DISCUSSION
We have previously reported excellent results with FDA vital staining on freshly examined sputum samples, reaching 92% PPV and 97% NPV for growth in culture. 4 These results were obtained in a reference laboratory on fresh specimens from Category I failures. We recommended the technique, followed by rapid slide DST, for early switch to second-line treatment and limiting referrals for DST to patients with FDA-positive sputum samples. There have been virtually no other reports on the use of FDA for TB, and to the best of our knowledge only our own project in Bangladesh uses this screening and early switch strategy. We report here our experience with the decentralised, routine use of FDA performed on all MDR-TB suspects identifi ed over a 3-year period. Since then, the technique has improved: LED fl uorescence microscopy was found to work better than conventional fl uorescence microscopy, as it permits scanning at 200× using the standard auramine excitation lamp and emission fi lter. The proportion of patients with confi rmed Rr who switched to second-line treatment increased from 60% to 83% of diagnosed cases. Moreover, the proportion of patients with confi rmed Rr who were identifi ed and who switched to second-line treatment before receiving Category II treatment tripled. Initially, a slightly higher number of cases were falsely diagnosed; however, this was soon reduced to the previous low levels, considered acceptable as the standard Bangladesh regimen is less toxic and cheaper. Moreover, our unpublished results show that the Bangladesh regimen produces equally good outcomes for non-confi rmed MDR-TB (RMP-and/or isoniazid-susceptible TB) compared to the reported results for MDR-TB. 5 5 (8) 4 (6) 6 (6) 12 (13) 11 (10) 8 (7) We have limited this report to FDA performance on AFB-positive sputum samples from late converters and failures during standard fi rst-line treatment, although other retreatment groups, such as relapses, were also initially targeted. Among these, FDA has the highest PPV, but fairly low NPV for viability (data not shown). Moreover, while Category I relapse rarely represents MDR-TB, Category II relapses in our population comprised equal proportions of pan-susceptible TB, MDR-TB and NTM. FDA was thus soon stopped for relapsed patients; Category I relapses were started on the Category II regimen with simultaneous slow DST; however, rapid-slide DST was performed for Category II relapses.
Our analysis shows that FDA screening may also be less useful in Category II failures with an unsatisfactory NPV for growth (83%, 95%CI 71-91) and 90% of false-negative FDA representing Rr or NTM. Rapid DST and identifi cation without FDA screening could thus be recommended for Category II failures, which have been reported to represent over 80% of MDR-TB cases from many populations. 12 FDA screening proved most useful in Category I late converters and failures. An NPV of at least 95% would allow us to avoid more than 60% of all DST referrals in our population. The small percentage with viable bacilli missed could be re-tested at a later occasion if still positive. Close to half of FDA-negative culture-positive late converters on Category I grew RMP-susceptible TB. A scanty FDA result may be ignored in case of these late converters awaiting further evolution, as most would not grow or yield susceptible bacilli, with only 16% predictive value for Rr.
The FDA PPV was high among Category I failures and Category II late conversions, a clearly positive (not scanty) result reaching 90% for Rr or NTM. In settings without NTM or with diffi cult DST access, a clearly positive FDA result could thus be a suffi cient indication to enrol a patient on cost-effi cient MDR-TB treatment. Given the logistical complications of DST, such as false-negative cultures, DST errors and mortality due to diffi cult and lengthy referrals, settings with access to DST may also benefi t from FDA. A strategy for switching to second-line treatment based on positive FDA smears in failures and late retreatment converters would be even more justifi ed in settings with higher MDR-TB prevalence among new cases than in our population, where it was only 0.5%. Differentiation between Rr and NTM would then be the main reason for further testing in settings where NTM are not very rare in these groups of MDR-TB suspects. This is not reliable using microscopy, 13 and a false diagnosis of NTM particularly might have serious consequences.
The Bangladesh NTP guidelines made better use of our FDA results impossible. The vast majority of FDA-negative Category I failures may not have needed the fi rst-line retreatment regimen to which they had to be automatically switched, even when only one AFB was found. The current World Health Organization (WHO) guidelines for TB control programmes recommend starting empirical second-line treatment for fi rst-line treatment failures while awaiting the results of conventional slow DST, or when DST is not possible. 14 In our case, this would have meant that over half of all second-line treatment regimens were given to cured patients.
Our study had some limitations. First, due to lack of data, we were unable to calculate the predictive value for relapse, which might have been indicated for late converters (failures had already been switched to the next higher treatment regimen based on AFB smear). It would seem likely that late conversion FDA-positive patients with RMP-susceptible TB are at increased risk for relapse with standard treatment. We have recently shown that extension of the intensive phase of Category I treatment does not prevent failures, but signifi cantly reduces relapse among smear-positives at 2 months of a regimen with RMP throughout. However, the predictive value for relapse of conventional AFB smears was only about 2%. 15 Half of the 3-month FDA-positive Category I cases in this study had RMP-susceptible TB, and it is possible that only these really benefi ted from intensive phase extension.
Second, the reference for growth on culture and Rr included slide DST, which is not a WHOr ecommended method. However, our previous study yielded very similar predictive values for growth on LJ culture only, and most samples reported here u nderwent slide DST as well as LJ DST at the SRL, with 90-95% agreement for Rr in the various laboratories. Considering any Rr as the true result might thus have led to slight over-diagnosis, meaning that the PPV of FDA for Rr might have been slightly overand the NPV slightly under-estimated.
The FDA technique is simple, but has some requirements, albeit far fewer than culture. With LED fl uorescence microscopes, the instrument and power supply no longer pose serious problems. However, FDA powder must be stored frozen at −20°C, as are stock solutions (or kept at 4°C for a few months), limiting its decentralised use in most settings to the intermediate level laboratory. Moreover, sputum needs to be fresh or kept refrigerated.
CONCLUSION
In contrast with conventional acid-fast smears, positive FDA results late during treatment were a strong predictor of failure to convert to negative culture and of RMP resistance. Decentralised use of the technique tripled the proportion of TB patients started early on second-line treatment. FDA vital staining can thus greatly improve the effi ciency of MDR-TB screening and diagnosis among smear-defi ned late converters and fi rst-time failures in settings with a low prevalence of RMP resistance, late case presentation and/ or highly sensitive acid-fast microscopy. With already high pre-test MDR-TB probability, a positive FDA test could even be considered as suffi cient evidence to start second-line treatment, particularly with a welltolerated regimen and low prevalence of NTM. Se pudieron evaluar 1633 episodios de conversión tardía y fracaso terapéutico definidos mediante la tinción con auramina (640 conversiones tardías y 584 fracasos en tratamientos iniciales y 185 conversiones tardías y 224 fracasos en pacientes en retratamiento). Un resultado negativo de la coloración con FDA pronosticó 95% de cultivos negativos en pacientes en tratamiento inicial y el valor pronóstico de un resultado po sitivo fue de 95% durante el retratamiento. El valor pronóstico de un resultado positivo (con excepción de las baciloscopias con bacilos escasos) para resistencia a RMP o presencia de micobacterias atípicas (NTM) fue como mínimo de 90%, con la excepción de las conversiones tardías de un tratamiento inicial. Un resultado negativo fue excluyente de las mismas en más del 95%, excepto en los fracasos del retratamiento. La tinción con diacetato de fluoresceína detectó en forma correcta de 88% a 98% de todas las resistencias a RMP. C O N C L U S I O N E S : La FDA aumentó la proporción de pacientes en quienes se administró un tratamiento de segunda línea sin haber recibido la pauta de retratamiento corriente de primera línea. En el entorno del estudio, con un servicio excelente de microscopia, una presentación tardía de los casos y una baja prevalencia de resistencia, esta prueba demostró ser indispensable para una eficacia máxima de los cultivos y remisiones rápidas con el fin de realizar pruebas de sensibilidad a los medicamentos en los casos con presunción temprana de resistencia. En otros medios, con baja prevalencia de NTM y dificultad de acceso a antibiogramas precisos y rápidos, los casos de fracaso con un resultado positivo a la FDA se podría incluso considerar el comienzo inmediato de un tratamiento de segunda línea.
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